#karxt — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #karxt, aggregated by home.social.
-
Ein neues Schizophrenie-Mittel setzt erstmals an den Muskarinrezeptoren des Hirns an. Es ist wirksamer und verträglicher als bisherige Präparate und jetzt in den USA zugelassen.#Schizophrenie #Psychose #Wahn #Antipsychotika #Neuroleptika #Psychopharmaka #KarXT #Medizin
»KarXT« macht Hoffnung -
Ein neues Schizophrenie-Mittel setzt erstmals an den Muskarinrezeptoren des Hirns an. Es ist wirksamer und verträglicher als bisherige Präparate und jetzt in den USA zugelassen.#Schizophrenie #Psychose #Wahn #Antipsychotika #Neuroleptika #Psychopharmaka #KarXT #Medizin
»KarXT« macht Hoffnung -
Ein neues Schizophrenie-Mittel setzt erstmals an den Muskarinrezeptoren des Hirns an. Es ist wirksamer und verträglicher als bisherige Präparate und jetzt in den USA zugelassen.#Schizophrenie #Psychose #Wahn #Antipsychotika #Neuroleptika #Psychopharmaka #KarXT #Medizin
»KarXT« macht Hoffnung -
Ein neues Schizophrenie-Mittel setzt erstmals an den Muskarinrezeptoren des Hirns an. Es ist wirksamer und verträglicher als bisherige Präparate und jetzt in den USA zugelassen.#Schizophrenie #Psychose #Wahn #Antipsychotika #Neuroleptika #Psychopharmaka #KarXT #Medizin
»KarXT« macht Hoffnung -
Cobenfy (KarXT): A More Atypical Antipsychotic for Treatment of Schizophrenia
Cobenfy (also known as KarXT), a combination of the drugs xanomeline and trospium chloride, has been studied to be effective for the treatment of...........
#Antipsychotic #Cobenfy #FDA #KarXT #Schizophrenia
Neelesh Prasad -
Cobenfy (KarXT): A More Atypical Antipsychotic for Treatment of Schizophrenia
Cobenfy (also known as KarXT), a combination of the drugs xanomeline and trospium chloride, has been studied to be effective for the treatment of...........
#Antipsychotic #Cobenfy #FDA #KarXT #Schizophrenia
Neelesh Prasad -
Cobenfy (KarXT): A More Atypical Antipsychotic for Treatment of Schizophrenia
Cobenfy (also known as KarXT), a combination of the drugs xanomeline and trospium chloride, has been studied to be effective for the treatment of...........
#Antipsychotic #Cobenfy #FDA #KarXT #Schizophrenia
Neelesh Prasad -
Cobenfy (KarXT): A More Atypical Antipsychotic for Treatment of Schizophrenia
Cobenfy (also known as KarXT), a combination of the drugs xanomeline and trospium chloride, has been studied to be effective for the treatment of...........
#Antipsychotic #Cobenfy #FDA #KarXT #Schizophrenia
Neelesh Prasad -
Cobenfy (KarXT): A More Atypical Antipsychotic for Treatment of Schizophrenia
Cobenfy (also known as KarXT), a combination of the drugs xanomeline and trospium chloride, has been studied to be effective for the treatment of...........
#Antipsychotic #Cobenfy #FDA #KarXT #Schizophrenia
Neelesh Prasad -
One of the most satisfying aspects of covering biotech as long as I have
is the opportunity to report on the long arc of drug development, from start to finish.
It’s not always pretty, and more often than not, it ends badly.But #KarXT, now #Cobenfy, is one of those drug stories with a happy ending.
I remember talking to #Steven #Paul in 2019 for a story about the phase 2 results,
which were pretty remarkable.
Paul was excited about what KarXT might mean for people with #schizophrenia,
but he was cautious because, as he warned me at the time,
clinical trials for psychiatric conditions are extraordinarily difficult to replicate.
Let’s wait to see what KarXT does in Ph3 trials, he said.
Now, we know.It’s been cool to follow and report on the KarXT story all these years.
From PureTech to Karuna to Bristol Myers Squibb,
and now, to #approval, where Cobenfy will have a meaningful impact on people living with schizophrenia ...-- Adam Feuerstein
https://x.com/adamfeuerstein/status/1839623238525055101 -
One of the most satisfying aspects of covering biotech as long as I have
is the opportunity to report on the long arc of drug development, from start to finish.
It’s not always pretty, and more often than not, it ends badly.But #KarXT, now #Cobenfy, is one of those drug stories with a happy ending.
I remember talking to #Steven #Paul in 2019 for a story about the phase 2 results,
which were pretty remarkable.
Paul was excited about what KarXT might mean for people with #schizophrenia,
but he was cautious because, as he warned me at the time,
clinical trials for psychiatric conditions are extraordinarily difficult to replicate.
Let’s wait to see what KarXT does in Ph3 trials, he said.
Now, we know.It’s been cool to follow and report on the KarXT story all these years.
From PureTech to Karuna to Bristol Myers Squibb,
and now, to #approval, where Cobenfy will have a meaningful impact on people living with schizophrenia ...-- Adam Feuerstein
https://x.com/adamfeuerstein/status/1839623238525055101 -
One of the most satisfying aspects of covering biotech as long as I have
is the opportunity to report on the long arc of drug development, from start to finish.
It’s not always pretty, and more often than not, it ends badly.But #KarXT, now #Cobenfy, is one of those drug stories with a happy ending.
I remember talking to #Steven #Paul in 2019 for a story about the phase 2 results,
which were pretty remarkable.
Paul was excited about what KarXT might mean for people with #schizophrenia,
but he was cautious because, as he warned me at the time,
clinical trials for psychiatric conditions are extraordinarily difficult to replicate.
Let’s wait to see what KarXT does in Ph3 trials, he said.
Now, we know.It’s been cool to follow and report on the KarXT story all these years.
From PureTech to Karuna to Bristol Myers Squibb,
and now, to #approval, where Cobenfy will have a meaningful impact on people living with schizophrenia ...-- Adam Feuerstein
https://x.com/adamfeuerstein/status/1839623238525055101 -
One of the most satisfying aspects of covering biotech as long as I have
is the opportunity to report on the long arc of drug development, from start to finish.
It’s not always pretty, and more often than not, it ends badly.But #KarXT, now #Cobenfy, is one of those drug stories with a happy ending.
I remember talking to #Steven #Paul in 2019 for a story about the phase 2 results,
which were pretty remarkable.
Paul was excited about what KarXT might mean for people with #schizophrenia,
but he was cautious because, as he warned me at the time,
clinical trials for psychiatric conditions are extraordinarily difficult to replicate.
Let’s wait to see what KarXT does in Ph3 trials, he said.
Now, we know.It’s been cool to follow and report on the KarXT story all these years.
From PureTech to Karuna to Bristol Myers Squibb,
and now, to #approval, where Cobenfy will have a meaningful impact on people living with schizophrenia ...-- Adam Feuerstein
https://x.com/adamfeuerstein/status/1839623238525055101 -
One of the most satisfying aspects of covering biotech as long as I have
is the opportunity to report on the long arc of drug development, from start to finish.
It’s not always pretty, and more often than not, it ends badly.But #KarXT, now #Cobenfy, is one of those drug stories with a happy ending.
I remember talking to #Steven #Paul in 2019 for a story about the phase 2 results,
which were pretty remarkable.
Paul was excited about what KarXT might mean for people with #schizophrenia,
but he was cautious because, as he warned me at the time,
clinical trials for psychiatric conditions are extraordinarily difficult to replicate.
Let’s wait to see what KarXT does in Ph3 trials, he said.
Now, we know.It’s been cool to follow and report on the KarXT story all these years.
From PureTech to Karuna to Bristol Myers Squibb,
and now, to #approval, where Cobenfy will have a meaningful impact on people living with schizophrenia ...-- Adam Feuerstein
https://x.com/adamfeuerstein/status/1839623238525055101 -
#FDA approves new class of drug to treat schizophrenia.
Schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) worldwide. This rate is 1 in 222 people (0.45%) among adults (2).
#KarXT is a dual M1/M4 muscarinic agonist that targets a region of the central nervous system that is thought to control the positive, negative and cognitive symptoms of schizophrenia.
-
#FDA approves new class of drug to treat schizophrenia.
Schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) worldwide. This rate is 1 in 222 people (0.45%) among adults (2).
#KarXT is a dual M1/M4 muscarinic agonist that targets a region of the central nervous system that is thought to control the positive, negative and cognitive symptoms of schizophrenia.
-
#FDA approves new class of drug to treat schizophrenia.
Schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) worldwide. This rate is 1 in 222 people (0.45%) among adults (2).
#KarXT is a dual M1/M4 muscarinic agonist that targets a region of the central nervous system that is thought to control the positive, negative and cognitive symptoms of schizophrenia.
-
#FDA approves new class of drug to treat schizophrenia.
Schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) worldwide. This rate is 1 in 222 people (0.45%) among adults (2).
#KarXT is a dual M1/M4 muscarinic agonist that targets a region of the central nervous system that is thought to control the positive, negative and cognitive symptoms of schizophrenia.
-
#FDA approves new class of drug to treat schizophrenia.
Schizophrenia affects approximately 24 million people or 1 in 300 people (0.32%) worldwide. This rate is 1 in 222 people (0.45%) among adults (2).
#KarXT is a dual M1/M4 muscarinic agonist that targets a region of the central nervous system that is thought to control the positive, negative and cognitive symptoms of schizophrenia.